16 August 2007
The global cardiovascular drug market is forecast to expand to US$116.3 billion in 2010, says a new report from URCH Publishing, a leading provider of pharmaceutical industry business information.
The report, Cardiovascular Pharmaceutical Market Trends 2007 to 2010 - Key market forecasts and growth opportunities, which is published today, says that although there will be growth of 5.3% over the next four years, there will be a slowing of growth due to continued patent expires of major products.
However, virtually all companies involved in this area will see solid sales growth of their cardiovascular portfolios. "Four of the top 10 cardiovascular companies in 2005 are forecast to grow their cardiovascular sales at a double-digit annual growth rate over the next five years," commented Steve Seget the report's author. "They are Sanofi-Aventis, Novartis, GlaxoSmithKline and Boehringer Ingelheim; however, Merck is forecast to see declining sales resulting in a fall from second to sixth place in the list of top cardiovascular companies by 2010".
The 112 page publication provides an excellent overview to the current and future market dynamics and size for drug treatments for cardiovascular-related disorders. Other key findings from the report include:
Cardiovascular Pharmaceutical Market Trends 2007 to 2010 - Key market forecasts and growth opportunities is available from URCH Publishing.